Free Trial

Astria Therapeutics Q3 2023 Earnings Report

Astria Therapeutics logo
$5.70 -0.36 (-5.94%)
As of 03/28/2025 04:00 PM Eastern

Astria Therapeutics EPS Results

Actual EPS
-$0.63
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

Astria Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Astria Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Remove Ads

Astria Therapeutics Earnings Headlines

Astria Therapeutics price target raised to $28 from $27 at Wedbush
Wedbush Keeps Their Buy Rating on Astria Therapeutics (ATXS)
Elon Tax Shock?
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
Astria Therapeutics (ATXS) Gets a Buy from Wedbush
TD Cowen Remains a Buy on Astria Therapeutics (ATXS)
See More Astria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Astria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astria Therapeutics and other key companies, straight to your email.

About Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

View Astria Therapeutics Profile

More Earnings Resources from MarketBeat